← All trials
NCT00796263
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2009
- Primary completion
- Apr 1, 2021
- Completion date
- Jul 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- South East Asia Research Collaboration with HawaiiLead sponsor
- PfizerCollaborator
- Gilead SciencesCollaborator
- ViiV HealthcareCollaborator
- MerckCollaborator
- South East Asia Research Collaboration with HawaiiReponsible party - principal investigator
- Thai Red Cross AIDS Research Centre, Bangkok, ThailandOverall official - principal investigator
- Thai Red Cross AIDS Research Centre, Bangkok, ThailandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.